Clinical trial · no report yet · Phase 3
CheckMate 331
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
- NCT02481830 ↗
- Completed
- Bristol-Myers Squibb
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Lung Cancer
- Interventions
- Nivolumab; Topotecan; Amrubicin
- Arms
- Arm A Nivolumab · Experimental
- Arm B Chemotherapy Topotecan · Active comparator
- Arm B Chemotherapy Amrubicin · Active comparator
- Enrollment
- 569
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Bristol-Myers Squibb with Ono Pharmaceutical Co., Ltd.
- Start
- Sep 14, 2015
- Primary completion
- Aug 17, 2018
- Results posted
- Yes
- Registry record
- NCT02481830 · updated Jul 27, 2023